

DATE: July 25, 2023

FROM: Barb Leetch, Region VIII Alzheimer's Coordinator

TO: Region VIII VP, Federation Presidents and Alzheimer's Coordinators

SUBJ: NARFE Region VIII Alzheimer's Association Report for June 2023

As of the end of June, the NARFE fundraising total was \$15,853,619. This amount includes the Longest Day totals and the Walk to End Alzheimer's for 2022. The total amount includes the money raised (\$78,610) from the NARFE teams participating in the 2022 Walk to End Alzheimer's and the donations received (\$2,625) from the Longest Day in 2022. Also, planned gifts received in FY 2023 in the amount of \$859,137 were posted. The planned gifts amount will be updated monthly as more gifts are received throughout the year. During the month of June, our members raised a total of \$20,371, down \$9,943 from donations received in June 2022. The amount raised by Region VIII in FY 2023 is \$18,558 which is up \$3,103 from the same reporting period in FY 2022. Below is the breakout by Federation for both reporting periods:

	FY 2023	FY 2022	Difference	
California	\$13,859	\$11,432	\$ 2,427	
Hawaii	\$ 2,209	\$ 1,642	\$ 567	
Nevada	\$ 2,490	\$ 2,381	\$ 109	
Total	\$18,558	\$15,455	\$ 3,103	

The new fundraising goal is \$16 million by December 31, 2025.

Fiscal Year 2023 covers the period July 1, 2022, through June 30, 2023.

<u>The Longest Day</u> was on June 21, 2023, and fundraising for this event is now closed. Thank you to everyone who donated to this fundraising event.

Walk to End Alzheimer's. The NARFE Goal for the 2023 Walks is \$100,000. To date, \$24,620 has been raised. Teams can now register for the walk this year at alz.org/narfewalks. The Walk is the largest fundraiser for Alzheimer's care, support, and research. The name "NARFE" should be included in the team's name. You do not need to walk in-order-to start or join a team. You will be making a difference! The place and date for the 2023 Walks in Region VIII are shown below.

Walk Location	2023 Walk Date
Aptos, CA	9/23/2023
Bakersfield, CA	10/21/2023
Chico, CA	10/14/2023
Escondido, CA	9/23/2023
Eureka, CA	10/14/2023
Fresno, CA	10/21/2023
Hermosa Beach, CA	10/7/2023
Huntington Beach, CA	11/4/2023
Imperial County, CA	11/19/2023
Irvine, CA	10/21/2023
Long Beach, CA	10/28/2023
Los Angeles, CA	10/28/2023
Merced, CA	10/7/2023
Modesto, CA	9/9/2023
Monterey, CA	10/7/2023
Orcutt, CA	9/30/2023
Oxnard, CA	9/23/2023
Palm Desert, CA	11/4/2023
Rancho Cucamonga, CA	10/14/2023
Rancho Mission Viejo	9/30/2023
Redding, CA	9/23/2023
Ridgecrest, CA	10/28/2023
Rohnert Park, CA	10/7/2023
Sacramento, CA	9/30/2023
San Diego, CA	10/7/2023
San Fernando Valley, CA	10/22/2023
San Francisco, CA	11/4/2023
San Jose, CA	10/14/2023
San Luis Obispo, CA	11/4/2023
San Ramon, CA (East Bay Area)	10/28/2023
Santa Barbara, CA	10/14/2023
Santa Monica, CA	10/22/2023
Stockton, CA	10/14/2023
Suisun City, CA	10/21/2023
Temecula Valley, CA	10/7/2023
Valencia, CA	10/7/2023
Visalia, CA	8/20/2023
West Lake Village, CA	10/21/2023
Yountville, CA (Napa)	9/9/2023
Yuba City, CA	9/9/2023
Kahului, HI	10/21/2023

Kapa'a, HI	8/26/2023
Hilo, HI	9/23/2023
Honolulu, HI	11/4/2023
Las Vegas, NV	10/28/2023
Sparks, NV	10/14/2023

CNN Health — July 6,2023

First Alzheimer's drug to slow disease progression gets full FDA approval, triggering broader Medicare coverage

"The US Food and Drug Administration on Thursday granted traditional full approval to the Alzheimer's drug Leqembi, the first medicine proven to slow the course of the memory-robbing disease.

The Centers for Medicare and Medicaid Services said Thursday that it will now expand coverage of the drug, broadening access for up to an estimated million people with early forms of the disease.

"Today's action is the first verification that a drug targeting the underlying disease process of Alzheimer's disease has shown clinical benefit in this devastating disease," Teresa Buracchio, acting director of the Office of Neuroscience in the FDA's Center for Drug Evaluation and Research, said in the announcement. "This confirmatory study verified that it is a safe and effective treatment for patients with Alzheimer's disease."

Leqembi, from drugmakers Eisai and Biogen, received accelerated approval in <u>January</u> based on evidence that it clears amyloid plaque buildups in the brain that are associated with Alzheimer's disease. But because of an earlier coverage decision by CMS, which provides insurance coverage for many elderly people with Alzheimer's through Medicare, the drug hasn't been widely used. It costs \$26,500 annually before insurance coverage.

"You had this treatment at your fingertips, and suddenly you had Medicare saying, 'Yeah, but you can't quite get access to that yet,' " said Joe Montminy, 59, who was diagnosed with younger-onset Alzheimer's in his early 50s. "Getting that insurance coverage is incredibly significant ... because having a treatment is awesome, but I can't afford to pay the \$26,000 cost."

The drug was approved only for people with early forms of Alzheimer's disease, those with mild cognitive impairment or mild dementia who have been confirmed to have amyloid plaques in their brains. Dr. Lawrence Honig, a professor of neurology at Columbia University Irving Medical Center, estimates that group constitutes about a sixth of the more than 6 million Americans currently diagnosed with Alzheimer's.

People with more advanced forms of the disease may not benefit from the drug, he said, and may face increased safety risks.

"It's not that we know it's not good for people with moderate or severe disease; it's just that we don't know," said Honig, who has consulted for drug companies working on Alzheimer's medicines.

Even for those who may benefit from the drug, Honig noted, it's not a cure; Leqembi was shown in an 18-month clinical trial to slow declines in cognitive ability and function by 27%.

"The treatments we have right now are just the beginning of a new era," Honig said. "We hope that we will have treatments that are more efficacious."

Please remember that Chapter dues CAN NOT be used for donations to the Alzheimer's Association. Even if the Chapter is closing, they cannot donate the funds to NARFE-Alzheimer's Research.

Donations collected from NARFE members should be sent to the Federation Alzheimer's Coordinator for submission to the Alzheimer's Association and not be held for another month.

Thank you so much for all your support to make it possible to improve the lives of so many others!

Regards,
Barb Leetch
barbleetch@aol.com
619-249-2380

NARFE/ALZHEIMER'S RESEARCH		BY REGION AND FE	BY REGION AND FEDERATION		
CONTRIBUTIONS					
JULY 1, 2022 THROUGH JUNE 30, 2023		PER ALZHEIMER'S ASSOCIATION			
NARFE HQ	\$0.00	FY 2023 PGA FIGUR	RES		
ANONYMOUS CASH	\$0.00				
REGION I	\$9,920.75	REGION VI	\$27,795.97		
Connecticut	\$1,140.50	Arkansas	\$5,793.00		
Maine	\$386.25	Louisiana	\$5,659.00		
Massachusetts	\$1,383.00	Oklahoma	\$3,665.29		
New Hampshire	\$4,280.00	Panama	\$0.00		
New York	\$2,231.00	Texas	\$12,678.68		
Rhode Island	\$100.00				
Vermont	\$400.00	REGION VII	\$10,163.66		
		Arizona	\$3,396.00		
REGION II	\$23,014.70	Colorado	\$5,603.90		
Delaware	\$1,540.00	New Mexico	\$693.76		
Dist. of Columbia	\$316.00	Utah	\$150.00		
Maryland	\$9,383.21	Wyoming	\$320.00		
New Jersey	\$2,994.86				
Pennsylvania	\$8,780.63	REGION VIII	\$18,557.50		
		California	\$13,858.50		
REGION III	\$23,294.36	Hawaii	\$2,209.00		
Alabama	\$2,724.50	Nevada	\$2,490.00		
Florida	\$2,906.63	Philippines	\$0.00		
Georgia	\$11,352.68				
Mississippi	\$4,402.04	INTERNATIONAL FEDERATION \$100.00		\$100.00	
Puerto Rico/	\$335.00				
Virgin Islands		REGION IX	\$25,344.73		
South Carolina	\$1,573.51	Alaska	\$0.00		
		Idaho	\$5,448.88		
REGION IV	\$22,743.51	Montana	\$605.00		
Illinois	\$6,684.40	Oregon	\$12,374.30		
Indiana	\$4,404.61	Washington	\$6,916.55		
Michigan	\$3,051.00				
Ohio	\$4,946.50	REGION X	\$84,711.62		
Wisconsin	\$3,657.00	Kentucky	\$5,790.60		
		North Carolina	\$4,791.00		
REGION V	\$47,900.42	Tennessee	\$5,474.50		
lowa	\$7,360.61	Virginia	\$56,399.86		
Kansas	\$12,751.55	West Virginia	\$12,255.66		
Minnesota	\$5,374.00				
Missouri	\$3,852.00	July 1, 2022 through	July 1, 2022 through June 30, 2023		
Nebraska	\$1,667.20				
North Dakota	\$6,052.59	TOTAL	\$293,547.22		
South Dakota	\$10,842.47	Compiled by Olivia A		al Report)	